Budesonide/Formoterol fumarate dihydrate

Tier C — Watch / trade

AstraZeneca

Originator

2000

First approval

Expiry (public)

No sales data

Peak sales

Small molecule

Type

Targets：ADRB2, GR

Brand：Alenia, Symbicort Turbuhaler, Symbicort

Indications (approved)：Chronic obstructive pulmonary disease, Asthma

Regional status

Approved

2006-07-21

Approved

2000-08-01

China

Approved

2004-11-17

Japan

Approved

2009-10-16

Factories producing this API12

Factories registered as producing this API in our sourcing network (RFQ records + product master), sorted by RFQ activity; the snapshot carries no cost or customer data.

12 producing factories on file — sign in to view the named list (factory details are not shown to guests).

Synthetic routes & intermediates

Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.

Frequently asked questions

What are the approved indications of Budesonide/Formoterol fumarate dihydrate?

Approved indications include: Chronic obstructive pulmonary disease, Asthma.

When does the Budesonide/Formoterol fumarate dihydrate patent expire?

No public expiry year is available for Budesonide/Formoterol fumarate dihydrate yet; this page updates once verified.

How do I get a quote for Budesonide/Formoterol fumarate dihydrate intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-27